Cable Hill Partners, LLC Viking Therapeutics, Inc. Transaction History

Cable Hill Partners, LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Aug 06, 2019	SELL	$7.67 - $10.63 $30,680 - $42,520	-4,000 Closed	0 $0
Q1 2019 May 10, 2019	SELL	$7.58 - $9.94 $6,064 - $7,952	-800 Reduced 16.67%	4,000 $40,000
Q4 2018 Feb 12, 2019	BUY	$7.16 - $16.21 $18,616 - $42,146	2,600 Added 118.18%	4,800 $37,000
Q3 2018 Nov 14, 2018	BUY	$9.7 - $19.65 $21,340 - $43,230	2,200 New	2,200 $34,000

474

66.2M

5.72M

3.39M

Ticker VKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,688,496
Market Cap $4.18B
Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...

Get notified when there are updates to the investment portfolio of Cable Hill Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Cable Hill Partners, LLC with notifications on news.